News | June 23, 2026
WuXi Biologics wins fourth EMA certification for Suzhou Biosafety Center
Clearing 19 biologics for Europe market
Clearing 19 biologics for Europe market
About 250+ women riders participate in the awareness ride where free breast screening camp were conducted
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
The company said the safety profile remained consistent with earlier studies and was considered manageable
The research underscores growing concern that the intersection of neurodevelopmental conditions and social disadvantage can significantly compound health risks across the life course
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Pharma powerhouse names Cecile Guegan interim finance chief
Bolstering neuroscience push with late-stage Tourette therapy
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
Subscribe To Our Newsletter & Stay Updated
